Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?

Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD). Tolv...

Full description

Bibliographic Details

Published in:	Childhood Kidney Diseases
Main Authors:	Hee Sun Beak, Min Hyun Cho
Format:	Article
Language:	English
Published:	Korean Society of Pediatric Nephrology 2023-12-01
Subjects:	child polycystic kidney, autosomal dominant tolvaptan
Online Access:	http://www.chikd.org/upload/ckd-23-021.pdf